Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Jun;63(0 1):S36–S43. doi: 10.1097/QAI.0b013e3182920031

Table 3.

Effects of the intervention on HPV incidence at 12-months follow-up

Crude HPV incidence:
At 12 months follow-up
Baseline – 12 months
Unadjusted
Percent
I
[N=153]
%
(n)
Unadjusted
Percent
C
[N=61]
%
(n)
Relative
Risk
Ratio
(95% CI) P-value Odds
Ratioa
(95% CI)b P-value

23.5%
(36)
39.3%
(24)
0.60 (0.39, 0.91) .02 0.37 (0.18, 0.77) 0.008